Polaryx Therapeutics, Inc. (PLYX) income statement
PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.51−0.10 (-6.21%)
Close on Nov 19, 2026Market cap $75.27MP/E –Yield –
Polaryx Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -193.7%
Financial strength
- Current ratio
- 8.62
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 844.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.89
- Dividend yield
- –
See a number that looks wrong?